Visara Secures Exclusive License for Neurotrophic Keratitis Therapy
Visara secured exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 from Wuhan Hiteck Biological Pharma. It plans to develop the therapy as VIS-102, its second clinical-stage program.
Story updates
11:07:37 AM UTC
SquawkNews
NovaBridge’s subsidiary Visara secured exclusive rights (ex-Greater China) to develop and commercialize VIS-102, a modified rhNGF therapy for neurotrophic keratitis, from Wuhan Hiteck. The deal includes upfront, milestone and tiered royalty payments.Material DetailsContext by AI AnalystThis is an e…